One approach to this problem has been the use of radiofrequency ablation of the AV node to create complete heart block, followed by implantation of a pacemaker. Symptom relief is good, with attendant ...

"Atrial fibrillation is an important clinical problem that is extremely prevalent in patients with heart failure," said lead investigator Dr Andrea Natale (Cleveland Clinic, OH). With many refractory ...

When high doses of AV blocking drugs are not successful to lower ventricular rates in the setting of atrial fibrillation, AV node ablation can be utilized. Remember that all atrial action potentials ...

Please provide your email address to receive an email when new articles are posted on . Rate control with AV junction ablation plus biventricular pacing improved survival among patients with permanent ...

Adding ethanol infusion to radiofrequency catheter ablation in patients with persistent atrial fibrillation (A-fib) eliminates parasympathetic responses as well as A-fib inducibility, according to ...

Atrioventricular (AV) junction ablation plus cardiac resynchronization therapy (CRT) reduces mortality in patients with symptomatic permanent atrial fibrillation (AF), a narrow QRS, and a recent heart ...

Dr. Bernard Lim, a cardiologist with Prairie Cardiovascular Consultants in Springfield, Ill., explains what an atrial fibrillation is, how you get it, what happens when you get it and how do to treat ...

A "pace-and-ablate" strategy substantially boosted survival for permanent atrial fibrillation (Afib) patients with a narrow QRS across the range of left ventricular ejection fraction (LVEF), the ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Atrial fibrillation is the most common arrhythmia worldwide, affecting millions of the general population.

The field of atrial fibrillation is evolving rapidly. Although a medical rhythm control strategy has not proven to be beneficial for survival, new interventional therapies have improved the rate of ...

ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 25, 2004--St. Jude Medical, Inc. (NYSE:STJ) announced today U.S. Food and Drug Administration (FDA) approval and first implants of the Frontier(TM) II ...